Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study

Clinical Trial Title: 
A phase Ill randomized trial investigating bortezomib (NSC #681239; IND #58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LLy).
Clinical Trial Protocol ID: 
15020404-IRBOI-CROI
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To compare event free survival in patients with newly diagnosed T-ALL and T-lymphoblastic lymphoma who are randomized to a modified ABFM (chemotherapy) backbone versus bortezomib plus the modified ABFM backbone.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 1 and 31 years of age.
  • Have newly diagnosed T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane